%	O
%	O
TITLE	O

MicroRNA	O
-	O
363	O
targets	O
myosin	O
1B	O
to	O
reduce	O
cellular	O
migration	O
in	O
head	O
and	O
neck	O
cancer	O
.	O

%	O
%	O
ABSTRACT	O

Squamous	O
cell	O
carcinoma	O
of	O
the	O
head	O
and	O
neck	O
(	O
SCCHN	O
)	O
remains	O
a	O
prevalent	B-Incidence_or_Prevalence
and	O
devastating	O
disease	O
.	O

Recently	O
,	O
there	O
has	O
been	O
an	O
increase	O
in	O
SCCHN	O
cases	O
that	O
are	O
associated	O
with	O
high	O
-	O
risk	O
human	O
papillomavirus	O
(	O
HPV	O
)	O
infection	O
.	O

The	O
clinical	O
characteristics	O
of	O
HPV	O
-	O
positive	O
and	O
HPV	O
-	O
negative	O
SCCHN	O
are	O
known	O
to	O
be	O
different	O
but	O
their	O
molecular	O
features	O
are	O
only	O
recently	O
beginning	O
to	O
emerge	O
.	O

MicroRNAs	O
(	O
miRNAs	O
,	O
miRs	O
)	O
are	O
small	O
,	O
non	O
-	O
coding	O
RNAs	O
that	O
are	O
likely	O
to	O
play	O
significant	O
roles	O
in	O
cancer	O
initiation	O
and	O
progression	O
where	O
they	O
may	O
act	O
as	O
oncogenes	O
or	O
tumor	O
suppressors	O
.	O

Previous	O
studies	O
in	O
our	O
laboratory	O
showed	O
that	O
miR	O
-	O
363	O
is	O
overexpressed	O
in	O
HPV	O
-	O
positive	O
compared	O
to	O
HPV	O
-	O
negative	O
SCCHN	O
cell	O
lines	O
,	O
and	O
the	O
HPV	O
type	O
16	O
-	O
E6	O
oncoprotein	O
upregulates	O
miR	O
-	O
363	O
in	O
SCCHN	O
cell	O
lines	O
.	O

However	O
,	O
the	O
functional	O
role	O
of	O
miR	O
-	O
363	O
in	O
SCCHN	O
in	O
the	O
context	O
of	O
HPV	O
infection	O
remains	O
to	O
be	O
elucidated	O
.	O
We	O
analyzed	O
miR	O
-	O
363	O
levels	O
in	O
SCCHN	B-Study_Cohort
tumors	I-Study_Cohort
with	I-Study_Cohort
known	I-Study_Cohort
HPV	I-Study_Cohort
-	I-Study_Cohort
status	I-Study_Cohort
from	O
The	O
Cancer	O
Genome	O
Atlas	O
(	O
TCGA	O
)	O
and	O
an	O
independent	B-Study_Cohort
cohort	I-Study_Cohort
from	I-Study_Cohort
our	I-Study_Cohort
institution	I-Study_Cohort
.	I-Study_Cohort

Cell	O
migration	O
studies	O
were	O
conducted	O
following	O
the	O
overexpression	O
of	O
miR	O
-	O
363	O
in	O
HPV	O
-	O
negative	O
cell	O
lines	O
.	O

Bioinformatic	O
tools	O
and	O
a	O
luciferase	O
reporter	O
assay	O
were	O
utilized	O
to	O
confirm	O
that	O
miR	O
-	O
363	O
targets	O
the	O
3	O
'	O
-	O
UTR	O
of	O
myosin	O
1B	O
(	O
MYO1B	O
)	O
.	O

MYO1B	O
mRNA	O
and	O
protein	O
expression	O
levels	O
were	O
evaluated	O
following	O
miR	O
-	O
363	O
overexpression	O
in	O
HPV	O
-	O
negative	O
SCCHN	O
cell	O
lines	O
.	O

Small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
knockdown	O
of	O
MYO1B	O
was	O
performed	O
to	O
assess	O
the	O
phenotypic	O
implication	O
of	O
reduced	O
MYO1B	O
expression	O
in	O
SCCHN	O
cell	O
lines	O
.	O
MiR	O
-	O
363	O
was	O
found	O
to	O
be	O
overexpressed	O
in	O
HPV	O
-	O
16	O
-	O
positive	O
compared	O
to	O
the	O
HPV	O
-	O
negative	O
SCCHN	O
tumors	O
.	O

Luciferase	O
reporter	O
assays	O
performed	O
in	O
HPV	O
-	O
negative	O
JHU028	O
cells	O
confirmed	O
that	O
miR	O
-	O
363	O
targets	O
one	O
of	O
its	O
two	O
potential	O
binding	O
sites	O
in	O
the	O
3	O
'	O
UTR	O
of	O
MYO1B	O
.	O

MYO1B	O
mRNA	O
and	O
protein	O
levels	O
were	O
reduced	O
upon	O
miR	O
-	O
363	O
overexpression	O
in	O
four	O
HPV	O
-	O
negative	O
SCCHN	O
cell	O
lines	O
.	O

Increased	O
miR	O
-	O
363	O
expression	O
or	O
siRNA	O
knockdown	O
of	O
MYO1B	O
expression	O
reduced	O
Transwell	O
migration	O
of	O
SCCHN	O
cell	O
lines	O
,	O
indicating	O
that	O
the	O
miR	O
-	O
363	O
-	O
induced	O
migration	O
attenuation	O
of	O
SCCHN	O
cells	O
may	O
act	O
through	O
MYO1B	O
downregulation	O
.	O
These	O
findings	O
demonstrate	O
that	O
the	O
overexpression	O
of	O
miR	O
-	O
363	O
reduces	O
cellular	O
migration	O
in	O
head	O
and	O
neck	O
cancer	O
and	O
reveal	O
the	O
biological	O
relationship	O
between	O
miR	O
-	O
363	O
,	O
myosin	O
1b	O
,	O
and	O
HPV	O
-	O
positive	O
SCCHN	O
.	O

%	O
%	O
METHODS	O

Patients	O

This	O
study	O
was	O
approved	O
by	O
the	O
Institutional	O
Review	O
Board	O
of	O
the	O
University	O
of	O
Pittsburgh	O
(	O
protocol	O
#	O
99	O
-	O
069	O
)	O
.	O

Written	O
informed	O
consent	O
was	O
obtained	O
from	O
all	O
pa	O
-	O
tients	O
.	O

No	O
children	O
were	O
enrolled	O
in	O
this	O
study	O
.	O

Bioinformatics	O

MicroRNA	O
data	O
were	O
extracted	O
from	O
The	O
Cancer	O
Gen	O
-	O
ome	O
Atlas	O
(	O
TCGA	O
)	O
Research	O
Network	O
portal	O
isoform	O
files	O
for	O
SCCHN	O
tumors	O
(	O
accessed	O
May	O
15	O
,	O
2013	O
)	O
.	O

The	O
reads	O
per	O
million	O
miRNAs	O
mapped	O
data	O
unit	O
was	O
evaluated	O
,	O
which	O
represents	O
each	O
miRNA	O
read	O
count	O
as	O
a	O
fraction	O
of	O
the	O
total	O
miRNA	O
population	O
for	O
a	O
particular	O
tumor	O
.	O

Multiple	O
reads	O
from	O
individual	O
isoforms	O
were	O
combined	O
into	O
a	O
single	O
read	O
count	O
.	O

The	O
HPV	O
-	O
status	O
of	O
TCGA	O
SCCHN	O
tumors	O
was	O
noted	O
according	O
to	O
the	O
cBio	O
Cancer	O
Genomics	O
Platform	O
SCCHN	O
database	O

SCCHN	O
tumors	O

Forty	B-Study_Cohort
-	I-Study_Cohort
one	I-Study_Cohort
SCCHN	I-Study_Cohort
tissues	I-Study_Cohort
were	I-Study_Cohort
obtained	I-Study_Cohort
from	I-Study_Cohort
patients	I-Study_Cohort
according	O
to	O
Institutional	O
Review	O
Board	O
protocol	O
#	O
99–	O

069	O
.	O

Upon	O
surgical	O
removal	O
,	O
a	O
portion	O
of	O
all	O
tissues	B-HPV_Sample_Type
was	O
sent	O
to	O
pathology	O
for	O
tumor	O
staging	O
and	O
the	O
remainder	O
was	O
flash	O
frozen	O
until	O
further	O
processing	O
.	O

Cell	O
lines	O
and	O
maintenance	O

The	O
HPV	O
-	O
negative	O
human	O
SCCHN	O
cell	O
lines	O
PCI13	O
and	O
PCI30	O
were	O
kindly	O
provided	O
by	O
Dr	O
.	O
Theresa	O
Whiteside	O
(	O
University	O
of	O
Pittsburgh	O
Cancer	O
Institute	O
,	O
Pittsburgh	O
,	O
PA	O
)	O
while	O
the	O
JHU028	O
and	O
JHU029	O
cell	O
lines	O
were	O
ob	O
-	O
tained	O
from	O
Dr	O
.	O
Joseph	O
A	O
.	O

Califano	O
(	O
Johns	O
Hopkins	O
Uni	O
-	O
versity	O
School	O
of	O
Medicine	O
,	O
Baltimore	O
,	O
MD	O
)	O
.	O

PCI13	O
and	O
PCI30	O
were	O
cultured	O
in	O
Dulbecco	O
'	O
s	O
Modified	O
Eagle	O
'	O
s	O
Medium	O
(	O
Lonza	O
,	O
Walkersville	O
,	O
MD	O
)	O
while	O
JHU028	O
and	O
JHU029	O
were	O
cultured	O
in	O
RPMI	O
-	O
1640	O
(	O
Lonza	O
)	O
.	O

All	O
cells	O
were	O
supplemented	O
with	O
10	O
%	O
heat	O
-	O
inactivated	O
FBS	O
,	O
1	O
X	O
penicillin	O
/	O
streptomycin	O
solution	O
(	O
Lonza	O
)	O
,	O
and	O
2	O
mM	O
L	O
-	O
glutamine	O
(	O
Gibco	O
)	O
.	O

Cell	O
lines	O
were	O
maintained	O
in	O
a	O
hu	O
-	O
midified	O
cell	O
incubator	O
at	O
37	O
°C	O
,	O
5	O
%	O
CO2	O
atmosphere	O
.	O

Transfections	O

Cells	O
were	O
seeded	O
to	O
50	O
%	O
confluency	O
in	O
6	O
-	O
well	O
plates	O
in	O
antibiotic	O
-	O
free	O
media	O
24	O
h	O
prior	O
to	O
transfection	O
.	O

Cells	O
were	O
transfected	O
with	O
50	O
nM	O
premiR	O
-	O
363	O
,	O
negative	O
pre	O
-	O
miR	O
control	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
)	O
,	O
or	O
50	O
nM	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
against	O
MYO1B	O
(	O
ThermoFisher	O
Scientific	O
,	O
San	O
Jose	O
,	O
CA	O
)	O
using	O
Lipofecta	O
-	O
mine	O
2000	O
(	O
Invitrogen	O
,	O
Carlsbad	O
,	O
CA	O
)	O
and	O
Opti	O
-	O
MEM®	O
(	O
Gibco	O
,	O
Grand	O
Island	O
,	O
NY	O
)	O
.	O

A	O
FAM	O
-	O
labeled	O
control	O
pre	O
-	O
miR	O
(	O
Applied	O
Biosystems	O
)	O
or	O
a	O
Block	O
-	O
it	O
fluorescent	O
oligonucleotide	O
with	O
no	O
human	O
homologous	O
sequences	O
(	O
Invitrogen	O
)	O
was	O
used	O
as	O
a	O
control	O
and	O
to	O
measure	O
trans	O
-	O
fection	O
efficiency	O
in	O
premiR	O
and	O
siRNA	O
experiments	O
,	O
re	O
-	O
spectively	O
.	O

Cells	O
were	O
harvested	O
48	O
h	O
after	O
transfection	O
and	O
RNA	O
and	O
proteins	O
were	O
isolated	O
for	O
various	O
assays	O
as	O
described	O
below	O
.	O

DNA	O
and	O
RNA	O
isolation	O

The	O
Dneasy	O
Blood	O
&	O
Tissue	O
kit	O
(	O
Qiagen	O
,	O
Valencia	O
,	O
CA	O
)	O
was	O
used	O
to	O
isolate	O
DNA	O
from	O
SCCHN	O
tissues	B-HPV_Sample_Type
according	O
to	O
the	O
manufacturer’s	O
protocol	O
.	O

Total	O
RNA	O
was	O
isolated	O
from	O
SCCHN	O
tissues	B-HPV_Sample_Type
and	O
cell	O
lines	O
grown	O
to	O
80	O
-	O
90	O
%	O
confluency	O
using	O
the	O
UltraspecTM	O
RNA	O
Isolation	O
System	O
(	O
Biotecx	O
,	O
Houston	O
,	O
TX	O
)	O
according	O
to	O
the	O
manufacturer’s	O
protocol	O
.	O

HPV	O
genotyping	O
and	O
quantitative	B-HPV_Lab_Technique
real	I-HPV_Lab_Technique
time	I-HPV_Lab_Technique
RT	I-HPV_Lab_Technique
-	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique

HPV	O
status	O
of	O
the	O
tumor	O
tissues	B-HPV_Sample_Type
was	O
assessed	O
using	O
the	O
MY09	O
/	O
MY11	O
primer	O
set	O
,	O
which	O
amplifies	O
a	O
conserved	O
re	O
-	O
gion	O
of	O
the	O
HPV	O
L1	O
gene	O
The	O
glyceraldehyde	O
-	O
3	O
-	O
phosphate	O
dehydrogenase	O
(	O
GAPDH	O
)	O
gene	O
was	O
used	O
as	O
a	O
loading	O
control	O
using	O
5′	O
-	O
CGACCACTTTGTCAAGCTCA	O
-	O
3′	O
as	O
the	O
forward	O
primer	O
and	O
5′	O
-	O
AGGGGTCTACATG	O
GCAACTG	O
-	O
3′	O
as	O
the	O
reverse	O
primer	O
.	O

All	O
PCR	B-HPV_Lab_Technique
reactions	I-HPV_Lab_Technique
were	I-HPV_Lab_Technique
performed	I-HPV_Lab_Technique
using	I-HPV_Lab_Technique
20	I-HPV_Lab_Technique
ng	I-HPV_Lab_Technique
template	I-HPV_Lab_Technique
DNA	I-HPV_Lab_Technique
,	I-HPV_Lab_Technique
200	I-HPV_Lab_Technique
μM	I-HPV_Lab_Technique
of	I-HPV_Lab_Technique
each	I-HPV_Lab_Technique
deoxynucleoside	I-HPV_Lab_Technique
triphosphate	I-HPV_Lab_Technique
(	I-HPV_Lab_Technique
dNTP	I-HPV_Lab_Technique
)	I-HPV_Lab_Technique
,	I-HPV_Lab_Technique
0	I-HPV_Lab_Technique
.	I-HPV_Lab_Technique
5	I-HPV_Lab_Technique
μM	I-HPV_Lab_Technique
of	I-HPV_Lab_Technique
each	I-HPV_Lab_Technique
primer	I-HPV_Lab_Technique
,	I-HPV_Lab_Technique
and	I-HPV_Lab_Technique
0	I-HPV_Lab_Technique
.	I-HPV_Lab_Technique
5	I-HPV_Lab_Technique
units	I-HPV_Lab_Technique
of	I-HPV_Lab_Technique
Taq	I-HPV_Lab_Technique
polymerase	I-HPV_Lab_Technique
and	I-HPV_Lab_Technique
the	I-HPV_Lab_Technique
associated	I-HPV_Lab_Technique
buffer	I-HPV_Lab_Technique
(	I-HPV_Lab_Technique
Promega	I-HPV_Lab_Technique
,	I-HPV_Lab_Technique
Madison	I-HPV_Lab_Technique
,	I-HPV_Lab_Technique
WI	I-HPV_Lab_Technique
)	O
.	O

Thermocycler	O
conditions	O
for	O
all	O
PCR	B-HPV_Lab_Technique
reactions	O
were	O
94	O
°C	O
for	O
5	O
min	O
;	O
35	O
cycles	O
of	O
94	O
°	O
C	O
for	O
30	O
s	O
,	O
57	O
°C	O
for	O
30	O
s	O
,	O
and	O
72	O
°C	O
for	O
30	O
s	O
;	O
and	O
72	O
°C	O
for	O
10	O
min	O
.	O

The	O
PCR	B-HPV_Lab_Technique
-	O
amplified	O
DNA	O
was	O
visualized	O
by	O
agarose	O
gel	O
electrophoresis	O
.	O

HPV	O
-	O
16	O
E6	O
,	O
HPV	O
-	O
16	O
E7	O
,	O
and	O
MYO1B	O
expression	O
levels	O
were	O
measured	O
by	O
quantitative	B-HPV_Lab_Technique
real	I-HPV_Lab_Technique
-	I-HPV_Lab_Technique
time	I-HPV_Lab_Technique
RT	I-HPV_Lab_Technique
-	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
(	I-HPV_Lab_Technique
qRT	I-HPV_Lab_Technique
-	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
)	I-HPV_Lab_Technique
using	I-HPV_Lab_Technique
the	I-HPV_Lab_Technique
iTaqTM	I-HPV_Lab_Technique
Universal	I-HPV_Lab_Technique
SYBR®	I-HPV_Lab_Technique
Green	I-HPV_Lab_Technique
One	I-HPV_Lab_Technique
-	I-HPV_Lab_Technique
Step	I-HPV_Lab_Technique
Kit	I-HPV_Lab_Technique
(	I-HPV_Lab_Technique
Bio	I-HPV_Lab_Technique
-	I-HPV_Lab_Technique
Rad	I-HPV_Lab_Technique
)	I-HPV_Lab_Technique
and	I-HPV_Lab_Technique
the	I-HPV_Lab_Technique
Real	I-HPV_Lab_Technique
-	I-HPV_Lab_Technique
Time	I-HPV_Lab_Technique
thermocycler	I-HPV_Lab_Technique
iQ5	I-HPV_Lab_Technique
(	I-HPV_Lab_Technique
Bio	I-HPV_Lab_Technique
-	I-HPV_Lab_Technique
Rad	I-HPV_Lab_Technique
,	I-HPV_Lab_Technique
Hercules	I-HPV_Lab_Technique
,	I-HPV_Lab_Technique
CA	I-HPV_Lab_Technique
,	I-HPV_Lab_Technique
USA	I-HPV_Lab_Technique
)	I-HPV_Lab_Technique
.	O

The	O
E6	O
forward	O
primer	O
5′	O
-	O
AATGTTTCAGGACCCACAGG	O
-	O
3′	O
,	O
E6	O
reverse	O
pri	O
-	O
mer	O
5′	O
-	O
CAGCTGGGTTTCTCTACGTG	O
-	O
3′	O
,	O
E7	O
forward	O
primer	O
5′	O
-	O
CATGGAGATACACCTACATTGCAT	O
-	O
3′	O
,	O

and	O
E7	O
reverse	O
primer	O
5′	O
-	O
GAACAGATGGGGCAC	O
ACAAT	O
-	O
3′	O
were	O
used	O
to	O
genotype	O
HPV	O
-	O
positive	O
SCCHN	O
tissue	B-HPV_Sample_Type
samples	I-HPV_Sample_Type
.	O

A	O
127	O
bp	O
region	O
of	O
the	O
MYO1B	O
gene	O
was	O
amplified	O
using	O
the	O
forward	O
primer	O
5′	O
-	O
GGTCTGGT	O
GTGGAGGTCCTA	O
-	O
3′	O
and	O
the	O
reverse	O
primer	O
5′	O
-	O
CGTTGCTTCCTCAGGTCTTC	O
-	O
3′	O
.	O

HPV	O
-	O
16	O
E6	O
,	O
HPV	O
-	O

16	O
E7	O
,	O
and	O
MYO1B	O
mRNA	O
levels	O
were	O
normalized	O
to	O
the	O
GAPDH	O
mRNA	O
levels	O
,	O
using	O
the	O
forward	O
primer	O
5′	O
-	O
CAGCCTCAAGATCATCAGCA	O
-	O
3′	O
and	O
the	O
reverse	O
pri	O
-	O
mer	O
5′	O
-	O
TGTGGTCATGAGTCCTTCCA	O
-	O
3′	O
,	O
amplifying	O
a	O
106	O
bp	O
region	O
.	O

DNase	O
I	O
-	O
treated	O
total	O
RNA	O
(	O
60	O
ng	O
)	O
was	O
used	O
for	O
each	O
reaction	O
,	O
and	O
all	O
the	O
reactions	O
were	O
per	O
-	O
formed	O
in	O
triplicate	O
.	O

Relative	O
mRNA	O
expression	O
levels	O
were	O
calculated	O
using	O
the	O
2	O
-	O
ΔΔCT	O
values	O

Mature	B-HPV_Lab_Technique
miR	I-HPV_Lab_Technique
-	I-HPV_Lab_Technique
363	I-HPV_Lab_Technique
expression	I-HPV_Lab_Technique
was	I-HPV_Lab_Technique
confirmed	I-HPV_Lab_Technique
by	I-HPV_Lab_Technique
qRT	I-HPV_Lab_Technique
-	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
using	I-HPV_Lab_Technique
the	I-HPV_Lab_Technique
TaqMan®	I-HPV_Lab_Technique
MicroRNA	I-HPV_Lab_Technique
Reverse	I-HPV_Lab_Technique
Transcrip	I-HPV_Lab_Technique
-	I-HPV_Lab_Technique
tion	I-HPV_Lab_Technique
Kit	I-HPV_Lab_Technique
and	I-HPV_Lab_Technique
the	I-HPV_Lab_Technique
TaqMan®	I-HPV_Lab_Technique
MicroRNA	I-HPV_Lab_Technique
Assays	I-HPV_Lab_Technique
(	I-HPV_Lab_Technique
Applied	I-HPV_Lab_Technique
Biosystems	I-HPV_Lab_Technique
,	I-HPV_Lab_Technique
Foster	I-HPV_Lab_Technique
City	I-HPV_Lab_Technique
,	I-HPV_Lab_Technique
CA	I-HPV_Lab_Technique
,	I-HPV_Lab_Technique
USA	I-HPV_Lab_Technique
)	I-HPV_Lab_Technique
and	I-HPV_Lab_Technique
the	I-HPV_Lab_Technique
Real	I-HPV_Lab_Technique
-	I-HPV_Lab_Technique
Time	I-HPV_Lab_Technique
thermocycler	I-HPV_Lab_Technique
iQ5	I-HPV_Lab_Technique
(	I-HPV_Lab_Technique
Bio	I-HPV_Lab_Technique
-	I-HPV_Lab_Technique
Rad	I-HPV_Lab_Technique
,	I-HPV_Lab_Technique
Hercules	I-HPV_Lab_Technique
,	I-HPV_Lab_Technique
CA	I-HPV_Lab_Technique
,	I-HPV_Lab_Technique
USA	I-HPV_Lab_Technique
)	I-HPV_Lab_Technique
.	O

The	O
qRT	B-HPV_Lab_Technique
-	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
experiments	O
utilized	O
stem	O
-	O
loop	O
primers	O
de	O
-	O
signed	O
to	O
amplify	O
processed	O
,	O
mature	O
miRNA	O
.	O

Total	O
RNA	O
(	O
50	O
ng	O
)	O
was	O
used	O
for	O
each	O
reaction	O
.	O

All	O
reactions	O
were	O

performed	O
in	O
triplicate	O
according	O
to	O
the	O
manufacturer’s	O
instructions	O
.	O

MiRNA	O
levels	O
for	O
each	O
sample	B-HPV_Sample_Type
were	O
nor	O
-	O
malized	O
to	O
small	O
nucleolar	O
(	O
sno	O
)	O
RNU43	O
levels	O
.	O

Relative	O
miRNA	O
expression	O
levels	O
were	O
calculated	O
using	O
the	O
2	O
-	O
ΔΔCT	O
values	O

Transwell	O
migration	O
assay	O

The	O
HPV	O
-	O
negative	O
SCCHN	O
cell	O
line	O
,	O
JHU028	O
,	O
was	O
trans	O
-	O
fected	O
with	O
premiR	O
-	O
363	O
or	O
an	O
siRNA	O
against	O
MYO1B	O
along	O
with	O
appropriate	O
controls	O
as	O
described	O
earlier	O
.	O

Forty	O
-	O
eight	O
hours	O
after	O
transfection	O
,	O
cells	O
were	O
harvested	O
and	O
reseeded	O
into	O
24	O
-	O
well	O
8	O
μM	O
pore	O
Transwell	O
inserts	O
(	O
Corning	O
)	O
in	O
serum	O
-	O
free	O
media	O
.	O

The	O
lower	O
chambers	O
of	O
the	O
Transwell	O
plate	O
were	O
filled	O
with	O
20	O
%	O
FBS	O
/	O
RPMI	O
media	O
to	O
serve	O
as	O
a	O
chemoattractant	O
.	O

Transwells	O
were	O
stained	O
with	O
0	O
.	O
1	O
%	O
crystal	O
violet	O
at	O
1	O
,	O
3	O
,	O
and	O
5	O
h	O
following	O
reseeding	O
.	O

Cells	O
were	O
photographed	O
under	O
the	O
micro	O
-	O
scope	O
and	O
counted	O
.	O

The	O
mean	O
of	O
eight	O
fields	O
from	O
four	O
separate	O
trials	O
was	O
used	O
to	O
calculate	O
the	O
average	O
number	O
of	O
migratory	O
cells	O
.	O

Mutagenesis	O
of	O
the	O
miR	O
-	O
363	O
binding	O
sites	O
in	O
the	O
MYO1B	O
3’	O
UTR	O

The	O
MYO1B	O
3’UTR	O
(	O
1	O
.	O
4	O
kb	O
;	O
chr2	O
:	O
192	O
,	O
288	O
,	O
687	O
-	O

192	O
,	O
290	O
,	O
115	O
)	O
was	O
PCR	B-HPV_Lab_Technique
amplified	O
using	O
the	O
forward	O
pri	O
-	O
mer	O
5’	O
-	O
GGACTAGTAACCGTCTCCTTGAAGTTGC	O
-	O
3’	O

and	O
the	O
reverse	O
primer	O
5′	O
-	O
GGAAGCTTGGCACAAG	O
GCAAGAAGAATC	O
-	O
3′	O
.	O

The	O
primers	O
were	O
designed	O
with	O
a	O
SpeI	O
restriction	O
site	O
on	O
the	O
forward	O
primer	O
and	O
a	O
Hin	O
-	O
dIII	O
site	O
on	O
the	O
reverse	O
primer	O
to	O
aid	O
in	O
directional	O
clon	O
-	O
ing	O
of	O
the	O
amplified	O
DNA	O
into	O
the	O
pMIR	O
-	O
REPORTTM	O
vector	O
(	O
Applied	O
Biosystems	O
)	O
.	O

The	O
orientation	O
of	O
the	O
inserted	O
fragment	O
was	O
confirmed	O
by	O
restriction	O
enzyme	O
digestion	O
and	O
sequencing	O
.	O

Deletion	O
primers	O
and	O
the	O
QuikChange	O
XL	O
Site	O
-	O
Directed	O
Mutagenesis	O
Kit	O
(	O
Agilent	O
Technologies	O
;	O
Santa	O
Clara	O
,	O
CA	O
)	O
was	O
used	O
to	O
delete	O
miR	O
-	O
363	O
binding	O
site	O
1	O
(	O
BS1	O
)	O
(	O
chr2	O
:	O
192	O
,	O
288	O
,	O
731	O
-	O
192	O
,	O
288	O
,	O
738	O
)	O
or	O
binding	O
site	O
2	O
(	O
BS2	O
)	O
(	O
chr2	O
:	O
192	O
,	O
289	O
,	O
618	O
-	O
192	O
,	O
289	O
,	O
625	O
)	O
from	O
the	O
3’UTR	O
of	O
the	O
MYO1B	O
gene	O
cloned	O
into	O
the	O
pMIR	O
-	O
REPORTTM	O
vector	O
(	O
Applied	O
Biosystems	O
)	O
.	O

BS1	O
was	O
deleted	O
using	O
the	O
forward	O
primer	O
5’	O
-	O
CTACTTTCATGGACTTGTTCCTTTGTAAT	O
A	O
-	O
TGGTTTTGTTTTATTTGGGGTTCATTGTATG	O
-	O
3’	O

and	O
the	O
reverse	O
primer	O
5’	O
-	O
CATACAATGAACCCCAAA	O
TAAAACAAAACCA	O
-	O
TATTACAAAGGAACAAGTCCA	O

TGAAAGTAG	O
-	O
3’	O
.	O

BS2	O
was	O
deleted	O
using	O
the	O
forward	O
primer	O
5’	O
-	O
CCATTCAGATAGCAGTAAAACATTCTG	O
TATGAT	O
-	O
AAACATCCAAGATCTTTTTTGAAAG	O
-	O
3’	O
and	O

the	O
reverse	O
primer	O
5’	O
-	O
CTTTCAAAAAAGATCTTGGAT	O
GTTT	O
-	O
ATCATACAGAATGTTTTACTGCTATCTGAA	O

TGG	O
-	O
3’	O
.	O

Deletion	O
mutants	O
were	O
confirmed	O
by	O
restriction	O
enzyme	O
digestion	O
and	O
DNA	O
sequencing	O
.	O

Luciferase	O
reporter	O
assay	O

HPV	O
-	O
negative	O
JHU028	O
cells	O
were	O
plated	O
at	O
30	O
,	O
000	O
cells	O
per	O
well	O
in	O
24	O
-	O
well	O
plates	O
(	O
Corning	O
)	O
.	O

After	O
24	O
h	O
,	O
cells	O
were	O
transfected	O
using	O
Lipofectamine	O
2000	O
(	O
Invitrogen	O
)	O
and	O
Opti	O
-	O
MEM®	O
(	O
Life	O
Technologies	O
)	O
.	O

The	O
pMIR	O
-	O
REPORTTM	O
MYO1B	O
wild	O
-	O
type	O
,	O
3’UTR	O
BS1	O
or	O
BS2	O
dele	O
-	O
tion	O
constructs	O
(	O
500	O
ng	O
)	O
were	O
co	O
-	O
transfected	O
with	O
20	O
ng	O
phRL	O
-	O
TK	O
and	O
50	O
nM	O
pre	O
-	O
miRs	O
.	O

All	O
transfection	O
experi	O
-	O
ments	O
were	O
repeated	O
at	O
least	O
four	O
times	O
.	O

Luciferase	O
activ	O
-	O
ity	O
was	O
measured	O
48	O
h	O
post	O
-	O
transfection	O
using	O
the	O
Dual	O
Luciferase	O
Reporter	O
Assay	O
System	O
(	O
Promega	O
)	O
according	O
to	O
manufacturer’s	O
instructions	O
and	O
the	O
Synergy	O
2	O
Lumin	O
-	O
ometer	O
(	O
Biotek	O
)	O
.	O

RLU	O
(	O
Firefly	O
/	O
Renilla	O
)	O
activity	O
was	O
nor	O
-	O
malized	O
to	O
the	O
MYO1B	O
wild	O
-	O
type	O
3’	O
UTR	O
co	O
-	O
transfected	O
with	O
phRL	O
-	O
TK	O
only	O
.	O

Western	O
blotting	O

Cells	O
were	O
lysed	O
with	O
radioimmunoprecipitation	O
assay	O
(	O
RIPA	O
)	O
buffer	O
at	O
4	O
°C	O
directly	O
on	O
the	O
6	O
well	O
-	O
plate	O
48	O
h	O
post	O
-	O
transfection	O
with	O
premiR	O
-	O
363	O
and	O
the	O
premiR	O
nega	O
-	O
tive	O
control	O
.	O

Proteins	O
(	O
50	O
μg	O
)	O
from	O
total	O
cell	O
lysates	O
were	O
separated	O
on	O
a	O
4	O
-	O
15	O
%	O
SDS	O
-	O
polyacrylamide	O
gradient	O
gel	O
(	O
Bio	O
-	O
Rad	O
)	O
and	O
transferred	O
to	O
Immobilon	O
-	O
P	O
PVDF	O
mem	O
-	O
brane	O
(	O
Millipore	O
,	O
Billerica	O
,	O
MA	O
)	O
.	O

After	O
blocking	O
,	O
blots	O
were	O
incubated	O
with	O
a	O
primary	O
rabbit	O
polyclonal	O
anti	O
-	O
body	O
against	O
MYO1B	O
and	O
a	O
secondary	O
anti	O
-	O
rabbit	O
horse	O
-	O
radish	O
peroxidase	O
antibody	O
(	O
both	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Santa	O
Cruz	O
,	O
CA	O
)	O
.	O

A	O
mouse	O
monoclonal	O
antibody	O
against	O
GAPDH	O
(	O
Chemicon	O
,	O
Billerica	O
,	O
MA	O
)	O
was	O
used	O
to	O
normalize	O
protein	O
loading	O
.	O

Blots	O
were	O
visualized	O
using	O
the	O
Western	O
Lightning	O
Plus	O
ECL	O
Substrate	O
(	O
Perkin	O
Elmer	O
;	O
Waltham	O
,	O
MA	O
)	O
,	O
developed	O
,	O
and	O
quantified	O
by	O
densitometry	O
using	O
AlphaView	O
software	O
by	O
ProteinSim	O
-	O
ple	O
(	O
Santa	O
Clara	O
,	O
CA	O
)	O
.	O

Statistical	O
analysis	O

Statistical	O
analysis	O
was	O
carried	O
out	O
using	O
two	O
-	O
tailed	O
t	O
-	O
tests	O
.	O

Data	O
was	O
considered	O
significant	O
at	O
a	O
value	O
of	O
p	O
<	O
0	O
.	O
05	O
.	O

